CD22 Flow Cytometry is a laboratory test that detects and measures the expression of CD22, a protein primarily found on B lymphocytes. Using flow cytometry, it helps identify and characterize B-cell populations in blood, bone marrow, or other specimens. The test is needed to support the diagnosis and classification of B-cell leukemias, lymphomas, and other lymphoproliferative disorders by evaluating abnormal patterns of cell-surface markers.
No. CD22 can be expressed by normal B lymphocytes. A positive result does not automatically indicate cancer and must be interpreted according to the overall cellular and clinical findings.
It may be recommended for individuals with unexplained abnormal blood counts, persistent lymphocytosis, enlarged lymph nodes, suspected leukemia or lymphoma, or other findings requiring B-cell characterization.
An abnormal result should be discussed with your treating physician or hematologist. The result may need correlation with other flow-cytometry markers, blood counts, clinical findings, and additional investigations.
Yes. Many B-cell lymphomas can express CD22. However, expression varies among different disorders, so additional markers are typically required for accurate classification.
Depending on the suspected condition, testing may include markers such as CD19, CD20, CD5, CD10, CD23, CD79b, kappa, lambda, and other B- or T-cell markers.
CD22 positivity indicates that the tested cells express the CD22 marker. The significance depends on which cells are positive and how CD22 expression compares with other markers.
CD22 negativity means that significant CD22 expression was not detected on the evaluated cell population. This finding should be interpreted as part of the complete flow-cytometry profile.
OTP sent to your mobile number on whatsapp
Didn't recieved OTP Yet? Resend OTP
